Merck & Co., Inc.
MRKPharma & biotechmsd.no
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Nov 4, 2026
Next reportFebruary 2, 2027after close · forecast 1.801 $/share
Revenue
$18.09B
▲ +4.7% vs prior year YoY
Net income
$5.07B
▼ -12.4% vs prior year YoY
EPS
2.04$
▼ -12.1% vs prior year YoY
Net margin
28.0%
▼ -5.5 pp vs prior year YoY
Revenue▲ +4.7%
Margins (% of revenue)GrossOperating N/ANet
Net income▼ -12.4%
EPS▼ -12.1%
Financial statements
View 10-Q filed November 4, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $15.62B | $15.53B | $15.81B | $17.28B | $16.40B | $16.29B | $16.61B | $18.09B | ▲ +4.7% |
| Gross profit | $11.80B | $12.11B | $12.25B | $13.42B | $10.85B | $12.09B | $12.21B | $13.19B | ▼ -1.7% |
| Operating incomenever filed | — | — | — | — | — | — | — | — | — |
| Net income | $3.74B | $5.08B | $4.43B | $5.79B | $2.96B | −$4.24B | −$1.33B | $5.07B | ▼ -12.4% |
| R&D | $4.58B | $3.62B | $4.05B | $4.23B | $3.89B | $12.59B | $9.74B | $4.54B | ▲ +7.2% |
| EPS (diluted) | — | 2.01 $ | 1.76 $ | 2.32 $ | — | -1.72 $ | -0.54 $ | 2.04 $ | ▼ -12.1% |
| Margins (% of revenue) | |||||||||
| Gross | 75.5 % | 78.0 % | 77.5 % | 77.7 % | 66.2 % | 74.2 % | 73.5 % | 72.9 % | ▼ -4.7 pt |
| Operating | — | — | — | — | — | — | — | — | — |
| Net | 24.0 % | 32.7 % | 28.0 % | 33.5 % | 18.1 % | -26.0 % | -8.0 % | 28.0 % | ▼ -5.5 pt |
| Balance sheet | |||||||||
| Assets | $117.11B | $115.12B | $117.52B | $129.55B | $136.87B | $128.69B | $129.80B | $132.77B | ▲ +2.5% |
| Liabilities | $70.73B | $66.72B | $68.46B | $77.64B | $84.20B | $82.75B | $87.82B | $87.83B | ▲ +13.1% |
| Equity | $46.37B | $48.40B | $49.06B | $51.91B | $52.66B | $45.93B | $41.98B | $44.95B | ▼ -13.4% |
| Cash | $13.24B | $8.63B | $8.01B | $18.17B | $14.56B | $5.33B | $6.85B | $9.55B | ▼ -47.4% |
| Capital | |||||||||
| Shares outstanding | 2.53B | 2.51B | 2.50B | 2.48B | 2.47B | 2.47B | 2.47B | 2.47B | ▼ -0.7% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.